<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018198</url>
  </required_header>
  <id_info>
    <org_study_id>13-0830</org_study_id>
    <nct_id>NCT02018198</nct_id>
  </id_info>
  <brief_title>FebriDx DISRUPT Acute Respiratory Infection Trial in Acute Respiratory Infection: An Evaluation of FebriDx® POC Test</brief_title>
  <official_title>DIStinguish Respiratory Underlying Pathogen associaTed Host Response in Acute Respiratory Infection: An Evaluation of FebriDx POC Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rapid Pathogen Screening</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumos Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine performance characteristics of the FebriDx test in&#xD;
      predicting viral or bacterial infection etiology among febrile (observed or reported)&#xD;
      patients presenting the emergency department, urgent care centers or primary care offices&#xD;
      with suspected acute respiratory tract infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, observational, blinded clinical trial whereby consented&#xD;
      study subjects will be enrolled into two study cohorts: an Acute Respiratory Infection cohort&#xD;
      and an Asymptomatic cohort. Subjects (children/adolescents, adults and elderly) with&#xD;
      suspected community acquired Acute Respiratory Infection will be enrolled in the Acute&#xD;
      Respiratory Infection cohort and subjects without infectious illness will be enrolled in the&#xD;
      Asymptomatic cohort. All subjects will undergo FebriDx testing (study device) and results,&#xD;
      blinded to subjects and treating physicians, will be compared to a Clinical Reference&#xD;
      Algorithm supervised by clinical experts to arbitrate the presence and type of infection&#xD;
      (bacterial or viral); the experts are also blinded to the results of FebriDx testing.&#xD;
&#xD;
      The FebriDx® test is a rapid, point-of-care (POC) test that uses a fingerstick blood sample&#xD;
      to identify patients with a pathogen induced host immune response through in-vitro detection&#xD;
      of both Myxovirus resistance protein A (MxA) and c-reactive protein (CRP) directly from a&#xD;
      whole blood sample. MxA is an intracellular protein that becomes elevated in the presence of&#xD;
      acute viral infection and CRP is an acute-phase inflammatory protein that is elevated in the&#xD;
      presence of a systemic bacterial and/or viral infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Actual">June 10, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is the presence of a bacterial associated systemic host immune response or viral associated systemic host immune response related to an acute community acquired febrile acute respiratory tract infection, as compared to final diagnosis</measure>
    <time_frame>10 minutes</time_frame>
    <description>The primary analysis will determine performance characteristics of the FebriDx® test by assessing negative and positive agreement of the FebriDx® results in determining the presence of a bacterial associated systemic host immune response or viral associated systemic host immune response compared with a Clinical Reference Algorithm (comparator method) that is supervised by clinical experts.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">540</enrollment>
  <condition>Acute Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Acute Respiratory Infection</arm_group_label>
    <description>Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices with a new onset, measured fever and new onset respiratory symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic Cohort</arm_group_label>
    <description>Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices without infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FebriDx</intervention_name>
    <description>Point of Care Host Immune Response Test</description>
    <arm_group_label>Acute Respiratory Infection</arm_group_label>
    <arm_group_label>Asymptomatic Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Respiratory and blood specimens will be retained for future testing.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting with a new onset, measured fever (exhibited or reported) and acute&#xD;
        respiratory symptoms&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Acute Respiratory Infection Cohort INCLUSION CRITERIA&#xD;
&#xD;
          -  1 year of age or older&#xD;
&#xD;
          -  Exhibit or report of a new onset measured temperature (oral or tympanic) of greater&#xD;
             than or equal to 100.5°F/38°C within 3 days (72 hours) of enrollment&#xD;
&#xD;
          -  Clinical suspicion for Acute Respiratory Infection and presents with at least one of&#xD;
             the following new onset of symptoms: runny nose, nasal congestion, sore throat, cough,&#xD;
             hoarse voice or shortness of breath beginning within 7 days before enrollment&#xD;
&#xD;
        Acute Respiratory Infection Cohort EXCLUSION CRITERIA&#xD;
&#xD;
          -  Incomplete or invalid testing for comparator method&#xD;
&#xD;
          -  Unwilling to participate&#xD;
&#xD;
          -  Receiving interferon therapy (e.g. MS, HIV, HBV, HCV) in the last 30 days&#xD;
&#xD;
          -  Immunocompromised state (e.g. HIV) or taking immunosuppressive or chemotherapeutic&#xD;
             medications in the last 30 days (e.g. oral steroids, Methotrexate, Cyclosporine,&#xD;
             Antimetabolite chemotherapy, interferon therapy)&#xD;
&#xD;
          -  Taking antibiotics or antiviral therapy in the last 14 days&#xD;
&#xD;
          -  Received a live viral immunization in the last 14 days&#xD;
&#xD;
          -  Significant trauma or burns (&gt; 5% total body surface area or full thickness (3rd°)) in&#xD;
             the last 30 days&#xD;
&#xD;
          -  Major surgery (requiring intravenous anesthesia and/or respiratory assistance) in the&#xD;
             last 30 days&#xD;
&#xD;
          -  Chronic fever without associated respiratory symptoms of greater than 7 days&#xD;
&#xD;
          -  History of ear pain plus an exam consistent with otitis media within the last 14 days&#xD;
&#xD;
          -  History of a myocardial infarction or stroke in the last 30 days&#xD;
&#xD;
        ASYMPTOMATIC COHORT INCLUSION CRITERIA&#xD;
&#xD;
          -  1 year of age or older&#xD;
&#xD;
          -  Absence of infectious signs and symptoms&#xD;
&#xD;
        ASYMPTOMATIC COHORT EXCLUSION CRITERIA&#xD;
&#xD;
          -  Fever greater than or equal to 100.5°F /38°C (oral or tympanic) in last 14 days&#xD;
&#xD;
          -  Cough&#xD;
&#xD;
          -  Chills&#xD;
&#xD;
          -  Dyspnea&#xD;
&#xD;
          -  Purulent Sputum&#xD;
&#xD;
          -  Fatigue&#xD;
&#xD;
          -  Pleuritic Pain&#xD;
&#xD;
          -  Nasal congestion&#xD;
&#xD;
          -  Rhinorrhea (runny nose)&#xD;
&#xD;
          -  Sore throat&#xD;
&#xD;
          -  Hoarse voice&#xD;
&#xD;
          -  Earache&#xD;
&#xD;
          -  Autoimmune or rheumatologic disease (e.g. undifferentiated connective tissue disease,&#xD;
             Rheumatoid Arthritis, Systemic Lupus Erythematosus (and subsets of Lupus), Sjögren's&#xD;
             syndrome, Systemic Sclerosis, Polymyositis and Dermatomyositis, Wegener's&#xD;
             granulomatosis)&#xD;
&#xD;
          -  Suspected of having any infection&#xD;
&#xD;
          -  Receiving interferon therapy (e.g. MS, HIV, HBV, HCV) in last 30 days&#xD;
&#xD;
          -  Immunocompromised state (e.g. HIV) or taking immunosuppressive (e.g. oral steroids,&#xD;
             Methotrexate, Cyclosporine, Antimetabolite chemotherapy, interferon therapy) in the&#xD;
             last 30 days&#xD;
&#xD;
          -  Taking antibiotics or antiviral therapy in the last 30 days&#xD;
&#xD;
          -  Received a live viral immunization in the last 30 days&#xD;
&#xD;
          -  Significant trauma or burns (&gt; 5% total body surface area or full thickness (3rd°)) in&#xD;
             the last 30 days&#xD;
&#xD;
          -  Major surgery (requiring intravenous anesthesia and/or respiratory assistance) in the&#xD;
             last 30 days&#xD;
&#xD;
          -  History of a myocardial infarction or stroke in the last 30 days&#xD;
&#xD;
          -  Chronic bacterial infection or osteomyelitis&#xD;
&#xD;
          -  Known chronic viral infections such as HIV, HCV, HBV, or CMV&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Acute or chronic (greater than 30 days) diarrhea and/or vomiting&#xD;
&#xD;
          -  Urinary tract symptoms in the last 14 days&#xD;
&#xD;
          -  Active diarrheal illness within the last 14 days&#xD;
&#xD;
          -  Active skin, ocular, or neurologic infections&#xD;
&#xD;
          -  Suspected of having otitis media&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Shapiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFC Urgent Care/Urgent Care Clinical Trials</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doral Medical Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAS Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodruff Road Urgent Care Center/Urgent Care Clinical Trials</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkside Pediatrics</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodruff Road Urgent Care Center, P.C./ Urgent Care Clinical Trials</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFC Urgent Care/Urgent Care Clinical Trials</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Office of Research and Development/Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urgent Care Clinical Trials</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison/Berbee Walsh Department of Emergency Medicine</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Joseph P, Godofsky E. Outpatient Antibiotic Stewardship: A Growing Frontier-Combining Myxovirus Resistance Protein A With Other Biomarkers to Improve Antibiotic Use. Open Forum Infect Dis. 2018 Feb 15;5(2):ofy024. doi: 10.1093/ofid/ofy024. eCollection 2018 Feb.</citation>
    <PMID>29479553</PMID>
  </results_reference>
  <results_reference>
    <citation>Shapiro NI, Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, Parekh AD, Kurz MC, Sambursky R. A prospective, multi-centre US clinical trial to determine accuracy of FebriDx point-of-care testing for acute upper respiratory infections with and without a confirmed fever. Ann Med. 2018 Aug;50(5):420-429. doi: 10.1080/07853890.2018.1474002. Epub 2018 May 18.</citation>
    <PMID>29775092</PMID>
  </results_reference>
  <results_reference>
    <citation>Self WH, Rosen J, Sharp SC, Filbin MR, Hou PC, Parekh AD, Kurz MC, Shapiro NI. Diagnostic Accuracy of FebriDx: A Rapid Test to Detect Immune Responses to Viral and Bacterial Upper Respiratory Infections. J Clin Med. 2017 Oct 7;6(10). pii: E94. doi: 10.3390/jcm6100094.</citation>
    <PMID>28991170</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Host Immune Response</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Point-of-Care</keyword>
  <keyword>Myxovirus Resistance Protein A (MxA)</keyword>
  <keyword>C-reactive Protein (CRP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

